We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Autoimmunity in Retinitis Pigmentosa

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified February 2007 by Semmelweis University.
Recruitment status was:  Active, not recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT00433277
First Posted: February 9, 2007
Last Update Posted: February 9, 2007
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Semmelweis University
  Purpose
Using local immune suppression, the trial seeks evidence for the hypothesis that autoimmunity plays a role in the pathomechanism of retinitis pigmentosa.

Condition Intervention
Retinitis Pigmentosa Drug: twice-daily dosage with 0.5% cyclosporine-A eyedrops

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)

Resource links provided by NLM:


Further study details as provided by Semmelweis University:

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Criteria

Inclusion Criteria:

  • Clinical diagnosis of retinitis pigmentosa

Exclusion Criteria:

  • Cataract
  • Extremely low ERG wave amplitude (less than 8% of normal)
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00433277


Locations
Hungary
Semmelweis University, Dept. of Ophthalmology
Budapest, Hungary, H-1085
Sponsors and Collaborators
Semmelweis University
Investigators
Study Director: Zoltán Z. Nagy, M.D. Semmelweis University, Dept. of Ophthalmology
  More Information

ClinicalTrials.gov Identifier: NCT00433277     History of Changes
Other Study ID Numbers: KMolnar
First Submitted: February 6, 2007
First Posted: February 9, 2007
Last Update Posted: February 9, 2007
Last Verified: February 2007

Additional relevant MeSH terms:
Retinitis
Retinitis Pigmentosa
Cone-Rod Dystrophies
Retinal Diseases
Eye Diseases
Eye Diseases, Hereditary
Retinal Dystrophies
Retinal Degeneration
Genetic Diseases, Inborn
Cyclosporins
Cyclosporine
Ophthalmic Solutions
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antifungal Agents
Anti-Infective Agents
Dermatologic Agents
Antirheumatic Agents
Calcineurin Inhibitors
Pharmaceutical Solutions